This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Flori, P. Articles by Sung, R. T. M. Search for Related Content PubMed PubMed Citation Articles by Flori, P. Articles by Sung, R. T. M.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, July 2004, p. 669-674, Vol. 11, No. 4
1071-412X/04/$08.00+0     DOI: 10.1128/CDLI.11.4.669-674.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Reliability of Immunoglobulin G Antitoxoplasma Avidity Test and Effects of Treatment on Avidity Indexes of Infants and Pregnant Women

Laboratory of Parasitology and Mycology,¹ Department of Neonatology and Pediatric Intensive Care Unit,² Department of Gynecology and Obstetrics, Hôpital Nord, University Hospital of Saint Etienne, France³

Received 29 August 2003/ Returned for modification 13 January 2004/ Accepted 30 March 2004

The immunoglobulin G antitoxoplasma avidity test (Vidas; BioMérieux) is an immunoenzymatic test useful for excluding acute infection after the onset of pregnancy. The avidity index (AI) is the ratio of the signal in a test sample washed with urea, which disrupts low-avidity complexes, to that washed without urea. An AI of >0.3 is taken to mean that infection had occurred more than 4 months ago. The increase of the AI with time and the influence of the different treatments given to pregnant women and their newborns were evaluated. A total of 59 pregnant women (271 sera) and their 60 neonates (199 sera) were tested from 1998 to 2002. There were five groups of women based on the type and duration of treatment given. Thirteen pregnant women (group 1) did not receive any treatment, 15 (group 2), 11 (group 3), and 17 (group 4) women received treatment with spiramycin (9 MIU/day) for 0.5 to 2, 2.5 to 5, and 5.5 to 8 months, respectively, and the last 3 women (group 5) received tritherapy (pyrimethamine-sulfonamide and spiramycin alternatively) for 1.5 to 2.5 months. All of the maternal sera collected in the first 6 months had an AI of <0.30, with a mean of 0.07 (range, 0.01 to 0.21). The increase was slow (0.02/month), and there was no significant difference when comparisons were made between the treatment groups. Neonates with proven maternofetal transmission had an increasing AI, unlike those without transmission. However, long-term therapy with pyrimethamine-sulfonamide, as opposed to treatment with spiramycin alone, was found to slow down the progression of the AI. An AI of >0.2 is sufficient to exclude acute infection in pregnant women. In neonates, it is not of major use to diagnose congenital infection; however, it could be a good indicator of compliance and efficacy of treatment of infected infants.

This article has been cited by other articles:

• Fox, J. L., Hazell, S. L., Tobler, L. H., Busch, M. P. (2006). Immunoglobulin G Avidity in Differentiation between Early and Late Antibody Responses to West Nile Virus. CVI 13: 33-36 [Abstract] [Full Text]